Down-regulation of Toll-like Receptor 4 Gene Expression by Short Interfering RNA Attenuates Bone Cancer Pain in a Rat Model

Overview

Journal Mol Pain

Date 2010 Jan 22

PMID 20089147

Citations 37

Authors

Liu Si Lan

Yang Jian Ping

Wang Li Na

Jiang Miao

Qiu Qiao Cheng

Ma Zhen Ni

Liu Lei

Li Cai Fang

Ren Chun Guang

Zhou Jin

Li Wei

Affiliations

Soon will be listed here.

Abstract

Background: This study demonstrates a critical role in CNS innate immunity of the microglial Toll-like receptor 4 (TLR4) in the induction and maintenance of behavioral hypersensitivity in a rat model of bone cancer pain with the technique of RNA interference (RNAi). We hypothesized that after intramedullary injection of Walker 256 cells (a breast cancer cell line) into the tibia, CNS neuroimmune activation and subsequent cytokine expression are triggered by the stimulation of microglial membrane-bound TLR4.

Results: We assessed tactile allodynia and spontaneous pain in female Sprague-Dawley (SD) rats after intramedullary injection of Walker 256 cells into the tibia. In a complementary study, TLR4 small interfering RNA(siRNA) was administered intrathecally to bone cancer pain rats to reduce the expression of spinal TLR4. The bone cancer pain rats treated with TLR4 siRNA displayed significantly attenuated behavioral hypersensitivity and decreased expression of spinal microglial markers and proinflammatory cytokines compared with controls. Only intrathecal injection of TRL4 siRNA at post-inoculation day 4 could prevent initial development of bone cancer pain; intrathecal injection of TRL4 siRNA at post-inoculation day 9 could attenuate, but not completely block, well-established bone cancer pain.

Conclusions: TLR4 might be the main mediator in the induction of bone cancer pain. Further study of this early, specific, and innate CNS/microglial response, and how it leads to sustained glial/neuronal hypersensitivity, might lead to new therapies for the prevention and treatment of bone cancer pain syndromes.

Citing Articles

Investigation of Correlation between Resistance to Diazepam and Expression of Inflammatory Markers in The Peripheral Blood of Patients with Status Epilepticus.

Mahama C, Louisa M, Octaviana F, Suryandari D, Budikayanti A, Wibowo H Acta Med Acad. 2024; 52(3):169-181.

PMID: 38407083 PMC: 10945326. DOI: 10.5644/ama2006-124.423.

Evidence of the Involvement of Spinal EZH2 in the Development of Bone Cancer Pain in Rats.

Chen H, Yu J, Hang L, Li S, Lu W, Xu Z J Pain Res. 2021; 14:3593-3600.

PMID: 34849017 PMC: 8627314. DOI: 10.2147/JPR.S331114.

Targeting the Oxytocinergic System: A Possible Pharmacological Strategy for the Treatment of Inflammation Occurring in Different Chronic Diseases.

Friuli M, Eramo B, Valenza M, Scuderi C, Provensi G, Romano A Int J Mol Sci. 2021; 22(19).

PMID: 34638587 PMC: 8508899. DOI: 10.3390/ijms221910250.

TLR4 Antagonism Reduces Movement-Induced Nociception and ATF-3 Expression in Experimental Osteoarthritis.

Ferreira-Gomes J, Garcia M, Nascimento D, Almeida L, Quesada E, Castro-Lopes J J Pain Res. 2021; 14:2615-2627.

PMID: 34466029 PMC: 8403032. DOI: 10.2147/JPR.S317877.

Sex differences in neuroimmune and glial mechanisms of pain.

Gregus A, Levine I, Eddinger K, Yaksh T, Buczynski M Pain. 2021; 162(8):2186-2200.

PMID: 34256379 PMC: 8277970. DOI: 10.1097/j.pain.0000000000002215.

References

Luger N, Honore P, Sabino M, Schwei M, Rogers S, Mach D . Osteoprotegerin diminishes advanced bone cancer pain. Cancer Res. 2001; 61(10):4038-47. View

Bettoni I, Comelli F, Rossini C, Granucci F, Giagnoni G, Peri F . Glial TLR4 receptor as new target to treat neuropathic pain: efficacy of a new receptor antagonist in a model of peripheral nerve injury in mice. Glia. 2008; 56(12):1312-9. DOI: 10.1002/glia.20699. View

Mao-Ying Q, Zhao J, Dong Z, Wang J, Yu J, Yan M . A rat model of bone cancer pain induced by intra-tibia inoculation of Walker 256 mammary gland carcinoma cells. Biochem Biophys Res Commun. 2006; 345(4):1292-8. DOI: 10.1016/j.bbrc.2006.04.186. View

Bonnet M, Erbacher P, Bolcato-Bellemin A . Systemic delivery of DNA or siRNA mediated by linear polyethylenimine (L-PEI) does not induce an inflammatory response. Pharm Res. 2008; 25(12):2972-82. DOI: 10.1007/s11095-008-9693-1. View

Elbashir S, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T . Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature. 2001; 411(6836):494-8. DOI: 10.1038/35078107. View

Chaplan S, Bach F, Pogrel J, Chung J, Yaksh T . Quantitative assessment of tactile allodynia in the rat paw. J Neurosci Methods. 1994; 53(1):55-63. DOI: 10.1016/0165-0270(94)90144-9. View

Grunweller A, Wyszko E, Bieber B, Jahnel R, Erdmann V, Kurreck J . Comparison of different antisense strategies in mammalian cells using locked nucleic acids, 2'-O-methyl RNA, phosphorothioates and small interfering RNA. Nucleic Acids Res. 2003; 31(12):3185-93. PMC: 162243. DOI: 10.1093/nar/gkg409. View

Liu X, Yao M, Li N, Wang C, Zheng Y, Cao X . CaMKII promotes TLR-triggered proinflammatory cytokine and type I interferon production by directly binding and activating TAK1 and IRF3 in macrophages. Blood. 2008; 112(13):4961-70. DOI: 10.1182/blood-2008-03-144022. View

Kawamata T, Omote K, Kawamata M, Iwasaki H, Namiki A . Antinociceptive interaction of intrathecal alpha2-adrenergic agonists, tizanidine and clonidine, with lidocaine in rats. Anesthesiology. 1997; 87(2):436-48. DOI: 10.1097/00000542-199708000-00035. View

10.

Schwei M, Honore P, Rogers S, Salak-Johnson J, Finke M, Ramnaraine M . Neurochemical and cellular reorganization of the spinal cord in a murine model of bone cancer pain. J Neurosci. 1999; 19(24):10886-97. PMC: 6784931. View

11.

Zhang R, Liu B, Wang L, Ren K, Qiao J, Berman B . Spinal glial activation in a new rat model of bone cancer pain produced by prostate cancer cell inoculation of the tibia. Pain. 2005; 118(1-2):125-36. DOI: 10.1016/j.pain.2005.08.001. View

12.

Raghavendra V, Tanga F, DeLeo J . Inhibition of microglial activation attenuates the development but not existing hypersensitivity in a rat model of neuropathy. J Pharmacol Exp Ther. 2003; 306(2):624-30. DOI: 10.1124/jpet.103.052407. View

13.

De Leo J, Tawfik V, LaCroix-Fralish M . The tetrapartite synapse: path to CNS sensitization and chronic pain. Pain. 2006; 122(1-2):17-21. DOI: 10.1016/j.pain.2006.02.034. View

14.

Tanga F, Raghavendra V, DeLeo J . Quantitative real-time RT-PCR assessment of spinal microglial and astrocytic activation markers in a rat model of neuropathic pain. Neurochem Int. 2004; 45(2-3):397-407. DOI: 10.1016/j.neuint.2003.06.002. View

15.

Miller T, Smith R, Kordasiewicz H, Kaspar B . Gene-targeted therapies for the central nervous system. Arch Neurol. 2008; 65(4):447-51. DOI: 10.1001/archneur.65.4.nnr70007. View

16.

Strang P . Cancer pain--a provoker of emotional, social and existential distress. Acta Oncol. 1999; 37(7-8):641-4. DOI: 10.1080/028418698429973. View

17.

Tsuda M, Toyomitsu E, Komatsu T, Masuda T, Kunifusa E, Nasu-Tada K . Fibronectin/integrin system is involved in P2X(4) receptor upregulation in the spinal cord and neuropathic pain after nerve injury. Glia. 2008; 56(5):579-85. DOI: 10.1002/glia.20641. View

18.

Yao M, Yang J, Wang L, Cheng H, Zhang Y, Xu Q . [Feasibility of establishment of rat model of bone cancer pain by using Walker 256 cells cultured in vitro or in vivo]. Zhonghua Yi Xue Za Zhi. 2008; 88(13):880-4. View

19.

Bradford M . A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976; 72:248-54. DOI: 10.1016/0003-2697(76)90527-3. View

20.

Urch C . The pathophysiology of cancer-induced bone pain: current understanding. Palliat Med. 2004; 18(4):267-74. DOI: 10.1191/0269216304pm887ra. View